PET scan test for EGFR-positive cancers using an antibody tracer
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tests a special PET scan agent (an antibody tracer) to help doctors see EGFR-positive cancers without needing invasive procedures. It is mainly for early testing (Phase 1/2) to understand how well it works for imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- Your cancer has EGFR-positive results confirmed by a pathology report.
- You have at least one tumor spot or lesion measuring 1.5 cm or larger.
- You must be able to sign consent and share your medical information.
- You should not be currently pregnant or breastfeeding (for people who could become pregnant, a negative urine pregnancy test is required).
- Your cancer treatments should not include prior anti-EGFR antibody therapy.
- You must be able to lie still and tolerate 60 minutes of PET scan imaging in each session.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new imaging agent, MNPR-101-DFO*-89Zr, can find solid tumors and measure their uPAR levels. It might help doctors better understand your cancer and guide future treatment decisions.
This trial is testing a new imaging probe that binds to EGFR mutations, which are common in some lung cancers. If you have lung cancer with a confirmed EGFR mutation, this scan may help doctors see your cancer more clearly.
This study tests if a new type of PET scan can see changes in your immune system when you receive immunotherapy for non-small cell lung cancer. It may help doctors understand how well your treatment is working.
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
This trial tests a new type of PET scan that uses a special tracer to find lung tumors. The goal is to see if this scan can better detect cancer cells, which may help doctors plan the best treatment for you.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.